Extending survival with chemotherapy in metastatic breast cancer
- PMID: 16368868
- DOI: 10.1634/theoncologist.10-90003-20
Extending survival with chemotherapy in metastatic breast cancer
Abstract
Metastatic breast cancer (MBC) remains essentially incurable, and goals of therapy include the palliation of symptoms, delay of disease progression, and prolongation of overall survival time without negatively impacting quality of life. Anthracycline and taxane-based therapies have traditionally shown the highest degree of activity in MBC. Though numerous randomized clinical trials have shown improvements in overall response rates, few have found clear survival benefits. In recent years, however, there has been a small but growing series of clinical trials demonstrating modest, but meaningful survival advantages in metastatic disease. A common feature in many of these trials has been the use of a taxane, and more recently, a taxane combined with an antimetabolite. In addition, the development of targeted biologic agents active against MBC, such as trastuzumab and bevacizumab, has demonstrated great potential for enhancing the effects of chemotherapy and producing meaningful survival improvements. The role of the taxanes, antimetabolites, and biologics in extending survival in MBC is discussed.
Similar articles
-
Lapatinib and ixabepilone for the treatment of metastatic breast cancer.Pharmacotherapy. 2008 Oct;28(10):1255-66. doi: 10.1592/phco.28.10.1255. Pharmacotherapy. 2008. PMID: 18823221 Review.
-
Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer.Breast Cancer Res Treat. 2008 Dec;112 Suppl 1:53-66. doi: 10.1007/s10549-008-0232-x. Epub 2008 Dec 20. Breast Cancer Res Treat. 2008. PMID: 19101794
-
First-line chemotherapy for metastatic breast cancer.Clin Breast Cancer. 2009 Jun;9 Suppl 2:S66-72. doi: 10.3816/CBC.2009.s.007. Clin Breast Cancer. 2009. PMID: 19596645 Review.
-
Trastuzumab: new indication. Metastatic breast cancer, in combination with docetaxel: promising, but more evaluation is needed.Prescrire Int. 2006 Feb;15(81):3-5. Prescrire Int. 2006. PMID: 16548094
-
[Chemotherapy for metastatic breast cancer].Zentralbl Gynakol. 2006 Dec;128(6):318-26. doi: 10.1055/s-2006-921561. Zentralbl Gynakol. 2006. PMID: 17213969 Review. German.
Cited by
-
Patient-derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis.J Mammary Gland Biol Neoplasia. 2016 Dec;21(3-4):99-109. doi: 10.1007/s10911-016-9361-8. Epub 2016 Sep 28. J Mammary Gland Biol Neoplasia. 2016. PMID: 27680982 Free PMC article.
-
Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer.Sci Rep. 2020 Jul 1;10(1):10757. doi: 10.1038/s41598-020-67431-6. Sci Rep. 2020. PMID: 32612272 Free PMC article. Clinical Trial.
-
Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil.Rev Saude Publica. 2022 Dec 9;56:100. doi: 10.11606/s1518-8787.2022056004160. eCollection 2022. Rev Saude Publica. 2022. PMID: 36515302 Free PMC article.
-
A prognostic 10-lncRNA expression signature for predicting the risk of tumour recurrence in breast cancer patients.J Cell Mol Med. 2019 Oct;23(10):6775-6784. doi: 10.1111/jcmm.14556. Epub 2019 Aug 20. J Cell Mol Med. 2019. PMID: 31429520 Free PMC article.
-
The Effect of Hyperthermia and Radiotherapy Sequence on Cancer Cell Death and the Immune Phenotype of Breast Cancer Cells.Cancers (Basel). 2022 Apr 19;14(9):2050. doi: 10.3390/cancers14092050. Cancers (Basel). 2022. PMID: 35565180 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
